Biotech News

Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine (PRME)Prime MedicineEarnings

-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1

Related news

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

Stock data

Close
3.84 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States